Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 4, 2012

Qiagen Buys AmniSure for Noninvasive Fetal Membrane Rupture Assay

  • Qiagen has bought AmniSure International for the Boston-based firm’s marketed AmniSure® assay for detecting rupture of fetal membranes (ROM) in pregnancy. About 30% of pregnant women are currently assessed for ROM, a condition in which amniotic fluid leaks from the amniotic sac prematurely, commonly leading to maternal and neonatal infections, as well as premature birth.

    The point-of-need AmniSure test comprises a one-step, minimally invasive test strip that can detect amniotic fluid in vaginal discharge within minutes. “This accurate diagnostic test contributes significant value in the management of pregnancy and adds to Qiagen’s portfolio of tests, in particular for the ob/gyn market,” comments Peer Schatz, CEO.

    AmniSure will operate as a wholly owned subsidiary of Qiagen. Acquisition of the business will add about $12 million to Qiagen’s sales sheet in 2012, and an expected $24 million in 2013. 



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »